GO:0006665 sphingolipid metabolic process: Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006665 sphingolipid metabolic process describes all chemical reactions and pathways involving sphingolipids, a class of lipids built on sphingosine or related sphingoid bases.
• Sphingolipid metabolism is a highly interconnected network that includes de novo synthesis, salvage/recycling, and breakdown, and it controls membrane structure, signaling, and cellular stress responses.
• Dysregulated sphingolipid metabolism is implicated in cancer, metabolic disease, liver fibrosis, neurodegeneration, and drug-induced toxicity.
• Key enzymes such as SPTLC1/2/3, ceramide synthases, sphingosine kinases, and ceramidases are attractive targets for genetic and pharmacological studies.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal testing of sphingolipid genes in disease-relevant cell types.
• Integrating lipidomics, transcriptomics, and functional genomics provides a systems-level view of sphingolipid metabolic process in health and disease.
Description
Sphingolipids are a diverse class of lipids that contain a long-chain amine diol, typically sphingosine or a closely related sphingoid base. The Gene Ontology term GO:0006665, sphingolipid metabolic process, encompasses the chemical reactions and pathways involving these molecules, including their synthesis, modification, transport, and degradation. This process is fundamental to eukaryotic life because sphingolipids are essential components of cellular membranes and potent bioactive signaling molecules. Researchers study sphingolipid metabolic process to understand how cells maintain membrane homeostasis, respond to stress, and regulate proliferation, differentiation, and death. The pathway is also a major source of therapeutic targets, as its dysregulation contributes to cancer, metabolic disorders, liver disease, and neuropathology. Advances in lipidomics, CRISPR genome editing, and functional genomics now allow precise interrogation of this complex network in physiologically relevant models.
sphingolipid metabolic process At A Glance
| GO ID | GO:0006665 |
|---|---|
| GO term | sphingolipid metabolic process |
| Ontology | biological_process |
| Synonym | sphingolipid metabolism |
| Definition | The chemical reactions and pathways involving sphingolipids, any of a class of lipids containing the long-chain amine diol sphingosine or a closely related base (a sphingoid). |
| Major function | Synthesis, interconversion, transport, and degradation of sphingolipids for membrane structure and signaling. |
| Key enzymes | Serine palmitoyltransferases (SPTLC1/2/3), ceramide synthases, sphingosine kinases, ceramidases, sphingomyelinases. |
| Subcellular locations | Endoplasmic reticulum, Golgi apparatus, plasma membrane, lysosomes, mitochondria-associated membranes. |
| Related processes | Ceramide metabolism, sphingosine-1-phosphate signaling, membrane lipid homeostasis, stress responses. |
What Is GO:0006665?
GO:0006665 sphingolipid metabolic process is defined as the chemical reactions and pathways involving sphingolipids, any of a class of lipids containing the long-chain amine diol sphingosine or a closely related base (a sphingoid). In practice, this term covers the biosynthesis of sphingoid bases, ceramides, and complex sphingolipids, as well as their interconversion, recycling, and breakdown into metabolites such as sphingosine-1-phosphate and ceramide. It is a biological process that integrates enzymatic reactions across multiple organelles, including the endoplasmic reticulum, Golgi apparatus, plasma membrane, and lysosomes.
Why Is sphingolipid metabolic process Important in Cell Biology?
Sphingolipid metabolic process is important because it controls the balance between structural membrane lipids and bioactive signaling molecules that influence cell fate. Ceramide, sphingosine, and sphingosine-1-phosphate act as second messengers in pathways governing proliferation, apoptosis, migration, and inflammation. Consequently, perturbations in this process are linked to cancer, metabolic syndrome, liver fibrosis, and drug-induced organ toxicity. Understanding the regulatory logic of sphingolipid metabolism is therefore essential for identifying therapeutic targets and biomarkers.
• Maintains membrane lipid composition and permeability, which are critical for organelle function and cell viability.
• Generates bioactive lipids such as ceramide and sphingosine-1-phosphate that regulate proliferation, apoptosis, and inflammation.
• Controls hepatic gluconeogenesis and systemic metabolic homeostasis through sphingolipid remodeling.
• Is implicated in the pathogenesis of liver fibrosis and is being explored as an anti-fibrotic target.
• Contributes to drug-induced hepatotoxicity, as shown for crizotinib via cholesterol/sphingolipid disturbance.
• Provides biomarkers and therapeutic targets in cancer and metabolic disease.
• Interacts with cholesterol metabolism and membrane trafficking, influencing signal transduction.
• Is amenable to CRISPR-based functional dissection of enzyme and transporter genes.
• Can be profiled by spatial and shotgun lipidomics to reveal tissue-specific roles.
• Offers opportunities for combination therapies targeting sphingolipid enzymes and oncogenic pathways.
What Happens During sphingolipid metabolic process?
De novo sphingolipid synthesis
In simple terms: The cell builds new sphingolipids from scratch starting with simple building blocks.
De novo synthesis begins in the endoplasmic reticulum with the condensation of serine and palmitoyl-CoA by serine palmitoyltransferase (SPT), a heteromeric enzyme containing SPTLC1, SPTLC2, or SPTLC3 subunits. This reaction produces 3-ketodihydrosphingosine, which is reduced to dihydrosphingosine (sphinganine) and then acylated by ceramide synthases to form dihydroceramide. Desaturation by dihydroceramide desaturase yields ceramide, the central hub of sphingolipid metabolism. SPTLC3 has been shown to regulate plasma membrane sphingolipid composition and hepatic gluconeogenesis.
Complex sphingolipid biosynthesis and trafficking
In simple terms: Ceramide is converted into more complex sphingolipids and moved to different cell membranes.
Ceramide is transported from the endoplasmic reticulum to the Golgi apparatus, where it is converted into sphingomyelin by sphingomyelin synthases or into glycosphingolipids by glycosyltransferases. These complex sphingolipids are then delivered to the plasma membrane and other organelles, contributing to membrane domain organization and signaling platforms. Sphingolipid-binding proteins facilitate their distribution and function in distinct cellular compartments.
Salvage and recycling pathways
In simple terms: The cell recycles sphingolipid breakdown products to make new sphingolipids.
Lysosomal and plasma membrane sphingolipids are degraded by acid sphingomyelinase, ceramidases, and glycosidases to release sphingosine and other sphingoid bases. Sphingosine can be re-acylated by ceramide synthases in the salvage pathway, recycling it back into ceramide and complex sphingolipids. This salvage route is quantitatively important and allows cells to rapidly adjust sphingolipid pools in response to stress and nutrient status.
Catabolism and bioactive lipid generation
In simple terms: Sphingolipids are broken down into signaling molecules that can affect cell behavior.
Ceramide can be hydrolyzed by ceramidases to sphingosine, which is phosphorylated by sphingosine kinases to sphingosine-1-phosphate (S1P). S1P can be dephosphorylated by S1P phosphatases or irreversibly degraded by S1P lyase, thereby terminating its signaling. Ceramide itself acts as a pro-apoptotic and stress-responsive lipid, while S1P promotes survival, migration, and angiogenesis. The balance between these metabolites determines cellular outcomes in physiology and disease.
Regulation and integration with cellular metabolism
In simple terms: The pathway is tuned by nutrients, stress, and signaling so the cell makes the right amount of each lipid.
Sphingolipid metabolism is regulated at multiple levels, including enzyme expression, post-translational modification, and substrate availability. Nutrient sensors and stress pathways influence flux through the pathway, and sphingolipid intermediates feed back on enzymes such as SPT and ceramide synthases. Spatial lipidomics has revealed tissue-specific remodeling of sphingolipid metabolism in liver fibrosis, highlighting its integration with disease-associated metabolic programs. Disturbance of cholesterol/sphingolipid metabolism by squalene epoxidase inhibition has been linked to crizotinib hepatotoxicity, illustrating crosstalk with other lipid pathways.
Key Genes Involved in GO:0006665 sphingolipid metabolic process
The following genes encode enzymes, transporters, and regulators that directly participate in or control sphingolipid metabolic process.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SPTLC1 | Subunit of serine palmitoyltransferase, first step of de novo synthesis | Target for knockout to block sphingolipid synthesis; linked to neuropathy |
| SPTLC2 | Catalytic subunit of serine palmitoyltransferase | Essential for de novo synthesis; studied in metabolic and cancer models |
| SPTLC3 | Regulates plasma membrane sphingolipid composition | Modulates hepatic gluconeogenesis; metabolic disease target |
| CERS1 | Ceramide synthase, produces very-long-chain ceramides | Role in stress responses and neurodegeneration |
| CERS2 | Ceramide synthase, synthesizes very-long-chain ceramides | Implicated in cancer and metabolic disease |
| CERS4 | Ceramide synthase with tissue-specific functions | Potential target in liver and skin biology |
| CERS5 | Ceramide synthase, generates C16 ceramide | Linked to apoptosis and insulin resistance |
| CERS6 | Ceramide synthase, generates C16 ceramide | Studied in cancer and inflammation |
| DEGS1 | Dihydroceramide desaturase, converts dihydroceramide to ceramide | Affects ceramide signaling and cell survival |
| SMPD1 | Acid sphingomyelinase, degrades sphingomyelin to ceramide | Deficiency causes Niemann-Pick disease; drug target |
| SMPD2 | Neutral sphingomyelinase | Regulates ceramide in stress responses |
| SMPD3 | Neutral sphingomyelinase | Role in bone and brain development |
| ASAH1 | Acid ceramidase, hydrolyzes ceramide to sphingosine | Deficiency causes Farber disease; cancer target |
| SPHK1 | Sphingosine kinase 1, produces S1P | Promotes survival and proliferation; cancer target |
| SPHK2 | Sphingosine kinase 2, produces S1P | Nuclear S1P signaling; apoptosis regulation |
| SGPL1 | S1P lyase, irreversible degradation of S1P | Regulates S1P gradients; knockout models available |
| SGPP1 | S1P phosphatase 1 | Terminates S1P signaling |
| UGCG | Glucosylceramide synthase, first step of glycosphingolipid synthesis | Target in cancer and lysosomal storage disorders |
How Is sphingolipid metabolic process Regulated?
Sphingolipid metabolic process is regulated by a combination of transcriptional, post-translational, and metabolic feedback mechanisms. Nutrient availability and stress signals modulate the expression and activity of key enzymes such as serine palmitoyltransferases and ceramide synthases. Sphingolipid intermediates themselves can feedback on upstream steps to maintain homeostasis. In liver, SPTLC3-dependent remodeling of plasma membrane sphingolipids influences gluconeogenesis, illustrating integration with systemic metabolic regulation. Additionally, crosstalk with cholesterol metabolism can perturb sphingolipid pathways, as observed with squalene epoxidase inhibition and crizotinib toxicity.
sphingolipid metabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SPTLC1 | Hereditary sensory neuropathy, sphingolipid imbalance | Knockout or point-mutation iPSC-derived neurons |
| SPTLC3 | Metabolic disease, hepatic gluconeogenesis | Liver-specific knockout or overexpression in hepatocytes |
| SMPD1 | Niemann-Pick disease, lysosomal storage disorder | Knockout cell lines and patient-derived fibroblasts |
| ASAH1 | Farber disease, ceramide accumulation | Knockout macrophages and iPSC-derived models |
| SPHK1 | Cancer, inflammation, S1P signaling | Overexpression and knockout cancer cell lines |
Sphingolipid metabolism in cancer
Altered sphingolipid metabolism is a hallmark of many cancers, where shifts in ceramide, sphingosine, and S1P levels promote survival, proliferation, and chemoresistance. Enzymes such as SPHK1, CERS2, and UGCG are frequently dysregulated and are being pursued as therapeutic targets. Targeting these enzymes can restore ceramide-mediated apoptosis and reduce tumor growth in preclinical models.
Metabolic and liver disease
Sphingolipid metabolism contributes to obesity, insulin resistance, and non-alcoholic fatty liver disease. SPTLC3 regulates plasma membrane sphingolipid composition to facilitate hepatic gluconeogenesis, linking sphingolipid remodeling to glucose homeostasis. Spatial lipidomics has identified sphingolipid metabolism as an anti-fibrotic target in the liver, suggesting that modulating this pathway could reduce fibrosis.
Drug-induced toxicity and neurodegeneration
Disturbing cholesterol/sphingolipid metabolism by squalene epoxidase inhibition can cause crizotinib hepatotoxicity, highlighting the pathway as a mediator of adverse drug reactions. Inherited defects in sphingolipid enzymes cause lysosomal storage disorders and neuropathies, including Niemann-Pick disease and Farber disease. These conditions underscore the importance of precise regulation of sphingolipid metabolic process for neuronal and organ health.
From sphingolipid metabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SPTLC3 alter hepatic gluconeogenesis? | Liver-specific SPTLC3 knockout in mice or hepatocyte cell lines |
| How does ceramide synthase isoform specificity affect apoptosis? | CERS knockout and point-mutation cell lines |
| Can restoring S1P balance reduce liver fibrosis? | S1P lyase or SPHK knockout in hepatic stellate cells |
| What is the role of SPTLC1 in neuropathy? | Knock-in of patient mutations in iPSC-derived neurons |
| Does UGCG overexpression promote chemoresistance? | UGCG overexpression and knockout cancer models |
| How does crizotinib affect sphingolipid metabolism? | CRISPR knockout of SQLE and lipidomic profiling |
How to Study the sphingolipid metabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Shotgun lipidomics | Global sphingolipid species abundance | Profiling disease models and drug responses |
| Spatial lipidomics | Sphingolipid distribution in tissue sections | Identifying anti-fibrotic targets in liver |
| CRISPR knockout screening | Gene requirement for sphingolipid phenotypes | Discovering modifiers of drug toxicity |
| RNA-seq | Transcriptional changes in sphingolipid genes | Pathway rewiring in metabolic disease |
| Proteomics | Protein abundance and modifications | Validating enzyme expression changes |
| Live-cell imaging | Subcellular localization and dynamics | Tracking ceramide and S1P trafficking |
| Enzyme activity assays | Catalytic activity of SPT, ceramidases, sphingosine kinases | Functional validation of variants |
| Metabolic flux analysis | Flux through sphingolipid pathways | Quantifying synthesis vs salvage |
Lipidomics and mass spectrometry
Shotgun and targeted lipidomics using mass spectrometry quantify sphingolipid species across cell and tissue samples. Spatial lipidomics can map sphingolipid distribution in tissues and has been used to identify anti-fibrotic targets in the liver. These methods are essential for validating genetic perturbations of sphingolipid metabolic process.
CRISPR functional genomics
CRISPR knockout, point-mutation, and knock-in models allow causal testing of individual sphingolipid genes. Pooled CRISPR screens can identify modifiers of sphingolipid-dependent phenotypes, such as drug sensitivity or lipid accumulation. These approaches are complemented by overexpression models to probe gain-of-function effects.
Transcriptomics and proteomics
RNA-seq and proteomics reveal how genetic or pharmacological perturbations reshape the expression of sphingolipid enzymes and related pathways. Integrating these datasets with lipidomic profiles provides a systems-level view of pathway regulation. Such multi-omics approaches are increasingly used in metabolic disease and cancer research.
Imaging and subcellular localization
Fluorescent sphingolipid analogs and tagged enzymes enable visualization of sphingolipid trafficking and enzyme localization. Live-cell imaging can track ceramide and S1P dynamics in response to stress or drugs. These methods complement biochemical assays to define where sphingolipid metabolic process occurs within cells.
How CRISPR Can Be Used to Study GO:0006665 sphingolipid metabolic process
Knockout
CRISPR knockout of sphingolipid enzymes such as SPTLC1, CERS isoforms, or SPHK1 enables loss-of-function studies to determine their role in cell survival, signaling, and disease phenotypes. Knockout models are particularly useful for validating whether a candidate gene is required for sphingolipid-dependent processes.
Point Mutation
Point mutations can model patient-derived variants in sphingolipid genes, such as those in SPTLC1 associated with neuropathy, to assess effects on enzyme activity and lipid profiles. These models help distinguish pathogenic from benign variants and guide precision medicine approaches.
Knock-in
Knock-in of tags or reporter sequences allows tracking of endogenous sphingolipid enzymes and their localization in real time. Knock-in of disease-associated mutations provides physiologically relevant models for studying sphingolipid metabolic process in specific cell types.
Overexpression
Overexpression of sphingolipid enzymes such as SPHK1 or UGCG can reveal gain-of-function phenotypes, including enhanced survival, chemoresistance, or altered lipid composition. These models complement knockout studies to define the directionality of pathway effects.
How EDITGENE Supports sphingolipid metabolic process Research
Researchers studying sphingolipid metabolic process-related genes often need to determine whether a candidate gene is causally involved in lipid remodeling, signaling, or disease phenotypes. EDITGENE provides CRISPR-based cell model services that enable precise genetic perturbations to answer these questions.
Contact EDITGENE today to design your custom CRISPR model for sphingolipid metabolic process research.
Frequently Asked Questions About sphingolipid metabolic process
What is GO:0006665 sphingolipid metabolic process?
GO:0006665 is a Gene Ontology biological process term defined as the chemical reactions and pathways involving sphingolipids, a class of lipids containing sphingosine or a related sphingoid base.
What genes are involved in sphingolipid metabolic process?
Key genes include SPTLC1, SPTLC2, SPTLC3, ceramide synthases (CERS1-6), DEGS1, SMPD1-3, ASAH1, SPHK1, SPHK2, SGPL1, SGPP1, and UGCG.
Why is sphingolipid metabolism important in cancer?
Altered sphingolipid metabolism shifts the balance between pro-apoptotic ceramide and pro-survival S1P, promoting tumor growth and chemoresistance.
How is sphingolipid metabolic process studied?
It is studied using lipidomics, CRISPR screens, transcriptomics, proteomics, imaging, and enzyme activity assays.
What diseases are linked to sphingolipid metabolism?
Diseases include cancer, metabolic syndrome, liver fibrosis, Niemann-Pick disease, Farber disease, and drug-induced hepatotoxicity.
What is the role of SPTLC3 in metabolism?
SPTLC3 regulates plasma membrane sphingolipid composition and facilitates hepatic gluconeogenesis.
Can CRISPR be used to study sphingolipid genes?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable causal testing of sphingolipid genes.
What is the difference between de novo synthesis and salvage in sphingolipid metabolism?
De novo synthesis builds sphingolipids from serine and palmitoyl-CoA, while salvage recycles sphingosine from degraded sphingolipids back into ceramide.
How does sphingolipid metabolism affect the liver?
Sphingolipid remodeling influences gluconeogenesis and fibrosis, and is being explored as an anti-fibrotic target.
What methods measure sphingolipid levels?
Mass spectrometry-based lipidomics, including spatial lipidomics, quantifies sphingolipid species in cells and tissues.
Conclusion
GO:0006665 sphingolipid metabolic process is a central biological pathway that governs membrane composition and bioactive lipid signaling. Its dysregulation is implicated in cancer, metabolic disease, liver fibrosis, and drug toxicity, making it a rich source of therapeutic targets. Advances in CRISPR genome editing and multi-omics profiling now allow researchers to dissect this complex network with unprecedented precision. Continued integration of genetic models with lipidomics will accelerate the translation of sphingolipid biology into clinical applications.
References
- 1. Kuo A et al.. 2024. Regulation of cellular and systemic sphingolipid homeostasis.. Nat Rev Mol Cell Biol 25(10):802-821 PMID: 38890457
- 2. Hannun YA et al.. 2018. Sphingolipids and their metabolism in physiology and disease.. Nat Rev Mol Cell Biol 19(3):175-191 PMID: 29165427
- 3. Green CD et al.. 2021. Sphingolipids in metabolic disease: The good, the bad, and the unknown.. Cell Metab 33(7):1293-1306 PMID: 34233172
- 4. Gruevska A et al.. 2025. Spatial lipidomics reveals sphingolipid metabolism as anti-fibrotic target in the liver.. Metabolism 168:156237 PMID: 40127860
- 5. Gault CR et al.. 2010. An overview of sphingolipid metabolism: from synthesis to breakdown.. Adv Exp Med Biol 688:1-23 PMID: 20919643
- 6. Snook CF et al.. 2006. Sphingolipid-binding proteins.. Biochim Biophys Acta 1761(8):927-46 PMID: 16901751
- 7. Yan H et al.. 2025. Disturbing Cholesterol/Sphingolipid Metabolism by Squalene Epoxidase Arises Crizotinib Hepatotoxicity.. Adv Sci (Weinh) 12(14):e2414923 PMID: 39836491
- 8. Montefusco D et al.. 2024. SPTLC3 regulates plasma membrane sphingolipid composition to facilitate hepatic gluconeogenesis.. Cell Rep 43(12):115054 PMID: 39661520
